ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
Nuclear Energy Conference & Expo (NECX)
September 8–11, 2025
Atlanta, GA|Atlanta Marriott Marquis
Standards Program
The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Latest Magazine Issues
Jul 2025
Jan 2025
Latest Journal Issues
Nuclear Science and Engineering
September 2025
Nuclear Technology
August 2025
Fusion Science and Technology
Latest News
Deep Space: The new frontier of radiation controls
In commercial nuclear power, there has always been a deliberate tension between the regulator and the utility owner. The regulator fundamentally exists to protect the worker, and the utility, to make a profit. It is a win-win balance.
From the U.S. nuclear industry has emerged a brilliantly successful occupational nuclear safety record—largely the result of an ALARA (as low as reasonably achievable) process that has driven exposure rates down to what only a decade ago would have been considered unthinkable. In the U.S. nuclear industry, the system has accomplished an excellent, nearly seamless process that succeeds to the benefit of both employee and utility owner.
Francisco J. Souto, Robert H. Kimpland, A. Sharif Heger
Nuclear Science and Engineering | Volume 150 | Number 3 | July 2005 | Pages 322-335
Technical Paper | doi.org/10.13182/NSE05-A2519
Articles are hosted by Taylor and Francis Online.
One of the primary methods to produce medical isotopes, such as 99Mo, is by irradiation of uranium targets in heterogeneous reactors. Solution reactors present a potential alternative to produce medical isotopes. The Medical Isotope Production Reactor (MIPR) concept has been proposed to produce medical isotopes with lower uranium consumption and waste than those in heterogeneous reactors. Commercial production of medical isotopes in solution reactors requires steady-state operation at ~200 kW. At this power regime, fuel-solution temperature increase and radiolytic-gas bubble formation introduce a negative reactivity feedback that has to be mitigated. A model based on the point reactor kinetic equations has been developed to investigate these reactivity effects. This model has been validated against experimental results from the Los Alamos National Laboratory uranyl fluoride Solution High-Energy Burst Assembly (SHEBA) and shows the feasibility of solution reactors for the commercial production of medical isotopes.
